Controversies in Multiple Sclerosis Therapy

Rizzo, Toni
June 2014
MD Conference Express;Jun2014, Vol. 14 Issue 6, p18
Academic Journal
Considerable progress has been made in multiple sclerosis (MS) therapy in the 20 years since the first successful trial. Although several agents are now available for treating patients with MS, many issues remain regarding treatment of individual patients. This article discusses initiating MS therapy, and addressed the issues of switching and escalating therapy and of discontinuing therapy.


Related Articles

  • Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study. Fernández, O.; Oreja-Guevara, C.; Arroyo, R.; Izquierdo, G.; Pérez, J.; Montalban, X. // Journal of Neurology;Sep2012, Vol. 259 Issue 9, p1814 

    Natalizumab has been shown to be effective in pivotal clinical trials in multiple sclerosis; however, the patients in whom treatment is indicated in clinical practice have a different clinical profile from those included in the clinical trials. The aim of this study is therefore to collect data...

  • Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis. Comi, Giancarlo; Filippi, Massimo; Rocca, Maria A.; Jeffery, Douglas; Kappos, Ludwig; Montalban, Xavier; Boyko, Alexey // New England Journal of Medicine;3/15/2012, Vol. 366 Issue 11, p1000 

    Background: Two proof-of-concept clinical trials have provided evidence that laquinimod reduces disease activity in patients with relapsing�remitting multiple sclerosis. Methods: We conducted a randomized, double-blind, phase 3 study at 139 sites in 24 countries. A total of 1106 patients...

  • Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. Kaufman, Michael; Cree, Bruce; Sèze, Jerome; Fox, Robert; Gold, Ralf; Hartung, Hans-Peter; Jeffery, Douglas; Kappos, Ludwig; Montalbán, Xavier; Weinstock-Guttman, Bianca; Ticho, Barry; Duda, Petra; Pace, Amy; Campagnolo, Denise // Journal of Neurology;Feb2015, Vol. 262 Issue 2, p326 

    The objective of this study is to characterize the timing and extent of radiologic MS disease recurrence during the 24-week natalizumab treatment interruption period in RESTORE. RESTORE was a randomized, partially placebo-controlled exploratory study. Natalizumab-treated patients with no...

  • Clinical consequences of MRI activity in treated multiple sclerosis. Cadavid, Diego; Kim, Soyeon; Peng, Bo; Skurnick, Joan; Younes, Maha; Hill, James; Wolansky, Leo J.; Cook, Stuart D. // Multiple Sclerosis Journal;Sep2011, Vol. 17 Issue 9, p1113 

    Background: Inflammation on brain MRI is the most sensitive marker of disease activity in multiple sclerosis (MS) but its clinical consequences remain controversial.Objective: Here we investigated the clinical consequences of MRI activity in MS subjects treated with two different first line...

  • Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review. Castillo-Trivino, Tamara; Braithwaite, Dejana; Bacchetti, Peter; Waubant, Emmanuelle // PLoS ONE;Jul2013, Vol. 8 Issue 7, p1 

    Background: Rituximab is an anti-CD20 monoclonal antibody approved for non Hodgkin lymphoma and rheumatoid arthritis. It is being considered for the treatment of MS. Objectives: To evaluate the efficacy and safety of rituximab for MS treatment. Data collection: Studies were selected if they were...

  • Frequent early multiple sclerosis relapses during treatment with fingolimod: a paradoxical effect? Ferraro, D; Federzoni, L; Vitetta, F; Simone, AM; Cossarizza, A; Nichelli, PF; Sola, P // Multiple Sclerosis Journal;Oct2013, Vol. 19 Issue 11, p1550 

    The article offers the authors' view on early relapses and manifestations of serious diseases in patients with multiple sclerosis (MS) during their treatment with fingolimod (FTY). They mention their administration of the immunomodulating drug to 11 patients between January and October 2012 who...

  • Merck reports encouraging data from Phase III multiple sclerosis trial.  // PharmaWatch: CNS;Aug2009, Vol. 8 Issue 8, p8 

    The article reports on the new data unveiled by Merck Serono SA from a two-year placebo-controlled Clarity Phase III trial which examined the efficacy of cladribine tablets in treating patients with relapsing-remitting multiple sclerosis. According to the data, the cladribine tablets can improve...

  • Phase III Study of Teva's Oral Laquinimod Published in the New England Journal of Medicine Demonstrates Clinical Benefits for Multiple Sclerosis Patients.  // Biomedical Market Newsletter;3/21/2012, Vol. 21, p1 

    The article informs that Teva Pharmaceutical Industries Ltd. has published its results for the laquinimod Phase III study in The New England Journal of Medicine. It mentions that the reduction of inflammatory disease activity by laquinimod was measured by clinical relapses and Magnetic Resonance...

  • Effects of Adjunct Low-Dose Vitamin D on Relapsing-Remitting Multiple Sclerosis Progression: Preliminary Findings of a Randomized Placebo-Controlled Trial. Shaygannejad, Vahid; Janghorbani, Mohsen; Ashtari, Fereshteh; Dehghan, Hamed // Multiple Sclerosis International;2012, p1 

    The aim of this preliminary study was to evaluate the effect of low-dose oral vitamin D in combination with current diseasemodifying therapy on the prevention of progression of relapsing-remitting multiple sclerosis (RRMS). A phase II double-blind placebo-controlled randomized clinical trial...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics